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Fluorescence imaging is an emerging clinical technique for real-time intraoperative
visualization of tumors and their boundaries. Though multiple fluorescent contrast agents
are available in the basic sciences, few fluorescence agents are available for clinical use.
Of the clinical fluorophores, delta aminolevulinic acid (5ALA) is unique for generating
visible wavelength tumor-specific fluorescence. In 2017, 5ALA was FDA-approved for
glioma surgery in the United States. Additionally, clinical studies suggest this agent may
have utility in surgical subspecialties outside of neurosurgery. Data from dermatology,
OB/GYN, urology, cardiothoracic surgery, and gastrointestinal surgery show 5ALA is
helpful for intraoperative visualization of malignant tissues in multiple organ systems.
This review summarizes data from English-language 5ALA clinical trials across surgical
subspecialties. Imaging systems, routes of administration, dosing, efficacy, and related
side effects are reviewed. We found that modified surgical microscopes and endoscopes
are the preferred imaging devices. Systemic dosing across surgical specialties range
between 5 and 30 mg/kg bodyweight. Multiple studies discussed potential for skin
irritation with sun exposure, however this side effect is infrequently reported. Overall,
5ALA has shown high sensitivity for labeling malignant tissues and providing a means to
visualize malignant tissue not apparent with standard operative light sources.
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INTRODUCTION
Surgeons have utilized light to better visualize their surgical fields
since antiquity. Fluorescence, a relatively new discovery, has been
studied since the early-to-mid twentieth century as a means for
providing better contrast of structures during surgery. Reports
from the late twentieth century showing fluorescence contrast
could improve intraoperative visualization of tumors during
surgery has fueled a renewed interest in further developing
clinical fluorescence imaging techniques.
In the United States, few agents are clinically approved
for generating intraoperative fluorescence contrast (1). Though
novel agents are in various stages of clinical trials, the three agents
currently approved for clinical use are fluorescein, indocyanine
green, and delta-aminolevulinic acid (5ALA), and of these, only
5ALA has a specific FDA clinical indication for CNS use (2).
Of these, 5ALA is also the only agent that produces intracellular
tumor-specific fluorescence. Delta-aminolevulinic acid generates
this fluorescence by causing tumor-specific accumulation of the
fluorescent molecule protoporphyrin IX (PpIX).
Delta-aminolevulinic acid is produced by the condensation of
succinate and glycine, and was first reported in a Nature article
in 1953 (3, 4). Studies with radiolabeled carbon showed this
molecule was involved in porphyrin synthesis (3). Studies during
the 1950s and 1960s focused on the role of 5ALA in the heme
synthesis pathway (5, 6). The first human studies with 5ALAwere
conducted in 1956, and were devised to study 5ALA metabolism.
In these studies, 5ALA was given orally (7). Skin sensitivity, a
well-known complication of 5ALA, was first reported in 1956 (7).
This phenomenon occurred 2–11 h after 5ALA administration.
Porphyrin-mediated fluorescence was first reported in the
late nineteenth century. However, the potential role porphyrins
would have in tumor visualization would not be reported
until half a century later in lab-based studies. The earliest
clinical studies of 5ALA-mediated tumor visualization were
reported for dermatology and urology in 1990 and 1994,
respectively (8–10). Throughout the remaining twentieth century
and early twenty first century, clinicians and scientists continued
to evaluate the role of 5ALA-mediated fluorescence for
intraoperative photodiagnosis of neoplasms in neurosurgery,
head and neck surgery, cardiothoracic surgery, gastrointestinal
surgery and OB/GYN.
This review provides a history of notable findings for 5ALA-
mediated photodiagnosis across surgical subspecialties. The
information is derived from a PubMed search of all English
language clinical trials published between 1950 and 2018. Basic
science and animal studies are excluded from this review.
NEUROSURGERY
First Application of 5ALA in Neurosurgery
The first study investigating 5ALA in neurosurgery was published
by Stummer et al. (11). In this seminal study, Stummer
administered 10 mg/kg of 5ALA orally to 9 patients with high-
grade gliomas (HGG) 3 h prior to induction of anesthesia. Using
a 375–440 nm bandpass filter, Stummer was able to provide
blue-light excitation. A long-pass filter >455 nm blocked the
reflected excitation light and allowed the emitted protoporphyrin
IX fluorescence to be visualized. From the 9 patients, Stummer
took a total of 89 biopsies; in these specimens, 5ALA
fluorescence demonstrated 85% sensitivity, 100% specificity, and
90% accuracy. The major contributors to the false-negatives were
areas of low-density infiltrates of malignant cells and necrotic
areas of the tumors. At the 10 mg/kg dose, no adverse effects
were recorded. This study, while small, established the utility of
5ALA as an intraoperative imaging agent and began a new era for
fluorescence-guided neurosurgery studies.
Landmark 5ALA Studies in Neurosurgery
Since the first paper in 1998, Stummer et al. and other
groups have continued to investigate various aspects of 5ALA
in neurosurgery. In 2000, Stummer et al. published a study
in a larger cohort of 52 patients with HGGs, this time
stratifying fluorescence subjectively into strong, vague, and none
(12). The study demonstrated again that 5ALA was highly
sensitive and specific for neoplasm and that residual fluorescence
after standard resection predicted subtotal resection, seen on
postoperative MRI as residual enhancement. The most impactful
clinical neurosurgery 5ALA study was the 2006 randomized,
controlled, multi-center trial by Stummer et al. (13). In the
study, 270HGGpatients were randomized to either fluorescence-
guided surgery with 5ALA or conventional surgery with white-
light alone. Importantly, the study demonstrated that those
in the 5ALA arm achieved gross total resection (GTR) at
a much higher rate (65% vs. 36%, p < 0.0001) and had
significantly higher progression-free survival (PFS) at 6 months
(41% vs. 21.1%, p = 0.0003) without significant changes
in postoperative neurologic deficits. Although the study was
underpowered to demonstrate effects on overall survival, the
results were nonetheless encouraging. In 2014, Coburger further
demonstrated that 5ALA was more accurate than intraoperative
MRI for detecting neoplasm at the infiltration zone, establishing
5ALA as both a more cost-effective and superior alternative (14).
Appropriate 5ALA Dose and Route of
Administration
The current accepted dose for 5ALA administration in
neurosurgery is an oral dose of 20 mg/kg bodyweight∼3 h before
induction of anesthesia, translating to roughly 4–5 h before
tumor exposure. In Stummer et al.’s first study in 1998, the dose
used was 10 mg/kg. Two later studies investigated different doses
of 5ALA in neurosurgery: a 2017 study by Stummer et al. (15)
and another 2017 study by Eljamel et al. (16). Stummer et al.
studied the efficacy of 0.2, 2, and 20mg/kg in a total of 21 patients
with HGGs and demonstrated that a 10-fold increase in dosage
from 2 to 20 mg/kg yielded only a 4-fold increase in signal.
They concluded that a dose higher than 20 mg/kg was unlikely
to yield significant benefits. Eljamel et al. on the other hand,
investigated doses from 10 to 50 mg/kg in 10 mg/kg increments
in 19 patients with HGGs. They concluded that a dose of up to
50 mg/kg was safe in patients and suggested that higher doses
of 5ALA may increase tumor fluorescence, although their results
were not statistically significant in their small sample population.
Considering these results, most groups, including Stummer et al.
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have transitioned to 20 mg/kg, which seems to be both safe
and effective.
In terms of route of administration, 5ALA has always
been administered orally for neurosurgical patients. Preclinical
studies, and studies in healthy patients, have established that
oral 5ALA is rapid and effective (17). Thus, changes to the
route of administration have not been considered for 5ALA
in neurosurgery.
Imaging 5ALA Fluorescence in
Neurosurgery
Neurosurgeons have relied heavily on surgical microscopes for
intracranial surgeries since the 1950s (18). Hence, the majority
of 5ALA visualization in neurosurgery has been performed with
surgical microscopes (Figure 1A). In general, add-on modules
are attached to existing microscopes to achieve blue-light
excitation. Initially, when Stummer et al. first described their
experience with 5ALA, a 375–440 nm bandpass filter was placed
in front of the Xenon light, which provided UV and blue-light
excitation. A long-pass >455 nm filter was used to block the
reflected excitation light, in order to better detect the red PpIX
fluorescence. This setup was used by Stummer’s group and other
groups until the mid-2000’s, when Zeiss introduced its Blue400
module, which uses a 400–410 nm filter for excitation and 620–
710 nm filter for emission and can rapidly toggle between white-
light and blue-light illumination. Band pass emission filters at
620–710 nm were initially utilized to specifically visualize the
peak red emission of PpIX; however, most surgeons found it
difficult to operate with red light only. Hence, emission filters
in the next generation of microscopes were changed from the
narrow band pass filter to a 444 nm long pass filter. Although
the field is illuminated only with blue light, autofluorescence in
green and mild yellow provide the surgeon with illumination
of surrounding background structures while resecting pink/red
fluorescent tissue (Figure 1B). Leica has recently offered its
FL400 module (380–430 nm excitation filter with a 444 nm long
pass emission filter), which, similar to the Zeiss module, provides
intraoperative visualization of PpIX.
Although exoscopes are a relatively new addition to
the neurosurgeons’ armamentarium, at least one group has
attempted 5ALA visualization using an exoscope. Piquer et al.
demonstrated that a commercial exoscope fitted with a 380–
430nm excitation filter and >444 nm emission filter could be
used to visualize 5ALA fluorescence reliably in the operating
room (19, 20). Their study remains one of few studies to visualize
5ALA fluorescence without standard microscope equipment.
Current Status of 5ALA
In June 2017, 5ALA was FDA-approved as an intraoperative
visualizing agent for patients with HGGs. Although 5ALA has
been difficult for U.S. neurosurgeons to access outside of research
studies, that is slowly changing as of April 2019 (2).
Future Applications of 5ALA Fluorescence
in Neurosurgery
Though most clinical 5ALA studies have focused on patients
with HGGs, some groups have investigated its application in
other intracranial tumors. For instance, Widhalm et al. (21, 22)
demonstrated that non-enhancing gliomas are poor targets for
5ALA and Valdes et al. (23) concluded that conventional 5ALA
imaging was of limited use in patients with low-grade gliomas.
On the other hand, Valdes et al. (24) and Coluccia et al. (25)
investigated the utility of 5ALA in meningiomas and concluded
that most meningiomas (80 and 94%, respectively) demonstrated
PpIX fluorescence. Similarly, Eljamel et al. concluded that 5ALA
fluorescence was useful in pituitary adenomas of various subtypes
(26). These studies offer encouraging evidence that 5ALA
fluorescence may be applicable to other intracranial tumors
and may further help neurosurgeons visualize tumors in the
operating room.
Technological advances are improving clinical 5ALA
fluorescence detection. Thus far, most neurosurgeons have
relied on qualitative grading of PpIX fluorescence (i.e., strong,
vague, none), which is limited in objectivity and sensitivity.
Multiple groups have demonstrated that quantitative grading of
fluorescence, achieved with an intraoperative spectrometry
probe, increases the sensitivity and accuracy of 5ALA
fluorescence (23, 24, 27). Furthermore, an important limitation
in 5ALA fluorescence is the micron-scale tissue penetration
by ultraviolent excitation light, which can hinder sensitive
tumor detection. Therefore, to increase depth penetration of
excitation light, Roberts et al. recently demonstrated that using
red-light excitation (620–640 nm) and a sensitive spectrally-
resolved camera to take advantage of 5ALA’s second, smaller
excitation/emission peak, neoplastic areas could be visualized up
to 5mm below the tissue surface (28).
Conclusion
Overall, 5ALA has demonstrated utility in increasing GTR rates
and PFS in patients with HGGs and may be applicable to other
intracranial tumors as well. Along with potential advances in
intraoperative visualization techniques, 5ALA may ultimately
improve patient outcomes in neurosurgery.
UROLOGY
First Application of 5ALA in Urology
The first study to evaluate 5ALA in Urology was published by
Kriegmair et al. (9). In this study, an intravesicular application
of 1.5 g of 5ALA dissolved in 50ml of sodium bicarbonate was
instilled. Time of exposure of 5ALA ranged from 15 to 360min.
The mean time between instillation and fluorescence cystoscopy
was 204min. Urologic surgery was performed under violet light
from a krypton ion laser with 406.7 nm excitation. This provided
visualization of red fluorescence from protoporphyrin IX in the
urothelium of the bladder to perform biopsies of the bladder wall
in 68 patients who were suspected to have bladder cancer. In
this study, photodynamic diagnosis utilizing 5ALA fluorescence-
directed urothelium biopsy diagnosed bladder cancer with a high
sensitivity of 100% and specificity of 68.5%. No serious side
effects were observed with intravesicular instillation of 5ALA.
This study generated confidence that 5ALA could provide highly
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FIGURE 1 | Fluorescence imaging in neurosurgery. (A) Zeiss Pentero fluorescence surgical microscope used for intraoperative imaging. (B) Brightfield illumination
compared to PpIX fluorescence from a malignant glioma, note fluorescence signal of the tumor compared to tumor margin and normal adjacent brain [Intraoperative
images courtesy of Stummer et al. (15)].
sensitive visualization and improved resection of difficult-to-
detect lesions, such as carcinoma in situ and urothelial dysplasia,
resulting in diminished recurrence rates.
Appropriate 5ALA Dose and Route of
Administration
5ALA can be administered via two routes for the diagnosis
of urologic malignancies. In early studies, a 1.5 g, 3% solution
of 5ALA was given almost exclusively by direct intravesicular
instillation 2–3 h before biopsy was performed. In more recent
studies, researchers have transitioned to administering a 20
mg/kg body weight oral solution of 5ALA 3–4 h before biopsy
is performed. Inoue et al. evaluated the safety and efficacy
of 10 mg/kg vs. 20 mg/kg of oral 5ALA in white light vs.
fluorescence cystoscopy in a total of 62 patients (29). The rates
of carcinoma in situ and high grade non-invasive papillary
urothelial carcinoma detected only by white light cystoscopy was
4.0 and 0.0%, respectively in the 10 and 20 mg/kg groups vs.
16.0 an 36.1%, respectively in the 10 and 20 mg/kg fluorescence
cystoscopy groups. Inoue et al. performed a follow-up study
in 2016 which demonstrated that sensitivity increased in a
dose-dependent manner with fluorescence cystoscopy, reporting
83.7% at ≧ 10 mg/kg and <15 mg/kg, 86.4% at ≧ 15 mg/kg and
<20 mg/kg, and 96.3% at≧ 20 mg/kg (30).
Imaging 5ALA Fluorescence in Urology
In the first study to document the results of 5ALA photodynamic
diagnostics in urologic malignancy, Kriegmair et al. utilized a
krypton ion laser 406.7 nm excitation. The majority of studies
published in this field utilize a xenon arc lamp with a 370–
440 nm bandpass filter, with or without long-pass filter to
detect the red PpIX fluorescence. A fluorescence cystoscope,
sometimes the help of a 0 or 30 telescope is typically employed
(Figure 2) (32, 33). Fukuhara et al. published a study in 2015
reporting the utility of a flexible fluorescence-cystoscope with
a twin-mode monitor in 5ALA photodynamic diagnosis of
bladder cancer (31). In this particular study, a new PDD
system consisting of a fluorescence endoscope with a SAFE-
3000 processor and flexible cystoscope with a xenon lamp
and semiconductor laser. Fluorescence images were observed
with a charge coupled device image processor. A twin-mode
monitor allowed a white light image and fluorescent image to be
visualized simultaneously.
Adverse Effects of 5ALA
Intravesicular application of 5ALA is overall, well-tolerated
with minimal side effects. Multiple studies reported transient
urinary urgency, pollakisuria, and alginuresis (34, 35). With
the oral administration of 5ALA, patients are often described
as having transient hypotension, transaminitis and skin
photosensitivity (29, 31, 36).
Limitations of 5ALA in Diagnosis of
Bladder Cancer
Speiss et al. reported in 2006 that fluorescence cystoscopy
with 5ALA can have a false-positive rate as high as 40% (37).
Possible causes of a false-positive result include: inflammation,
urothelial hyperplasia, recent urethral stents, bacteriuria,
previous intravesicular therapy within the previous 3 months,
and inexperience of the performing Urologist (38, 39).
Current Status of 5ALA in Urology
The United Stated Food and Drug Administration approved
5ALA for intra-operative photodynamic diagnosis of bladder
cancers in 1999. Currently, studies are being conducted regarding
the use of a 5ALA ester, hexyl aminolevulinate, to compare
efficacy and diagnostic accuracy.
Conclusion
Overall, 5ALA has demonstrated increased sensitivity in
diagnosis of bladder cancers compared to white-light cystoscopy,
especially in the case of carcinoma in situ and dysplasia. It has
shown to improve visualization of surgical margins at resection
and to decrease recurrence rates.
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FIGURE 2 | Fluorescence imaging in urology. (A) Karl Stortz D-light C used for blue-light cystoscopy as an adjunct to white-light cystoscopy for detection of
non-muscle invasive bladder cancer in patients with suspected or known lesion(s). (B) White light mode (left side) and blue light mode (right side) images of bladder
cancer simultaneously observed using twin mode monitor. Flat lesions show red florescence. (C) White light mode (left side) and blue light mode (right side) images of
bladder neck using turned back flexible cystoscopy in a vertical direction. No red fluorescence observed [Intraoperative images courtesy of Fukuhara et al. (31)].
DERMATOLOGY
First Application in Clinical Dermatology
The first study investigating 5ALA in dermatology was published
by Kennedy et al. (40). Though this study was designed to
evaluate the role of 5ALA in photodynamic therapy, fluorescence
was reported from tumor areas. In this study, 5ALA was applied
topically in a 20% solution to basal cell carcinoma (BCC)
lesions. After waiting 3 h, the lesions underwent light exposure.
Their initial results were promising. In the first 80 lesions that
were treated using this technique, 90% of the lesions had a
complete response rate and 7.5% had a partial response rate
following a single treatment (40). Significant interest in the
dermatologic utility of 5ALA has steadily grown since the work
of Kennedy et al.
Landmark 5ALA Studies in Dermatology
Szeimies et al. evaluated tissue localization of protoporphyrin
(Pp IX) after topical application of ALA by measuring the
fluorescence in different histological types of BCC lesions in
1994. These investigators used a 10% 5ALA and 10% CAB-
OSIL M-5 (highly dispersed SiO2, CAB-OSIL Division, Cabot
GmbH, Hanau, Germany) in propylene glycol ointment on
fifteen patients with BCC lesions undergoingMohsmicrosurgical
resection (MMS). The area was bandaged after applying 5ALA
ointment. Patients then underwent MMS 4–12 h after applying
the 5ALA ointment. The control patients did not receive
5ALA prior to MMS. A microscope equipped with a 515–
560 nm excitation filter was used during the MMS. The site
of red fluorescence was compared to the histopathology. The
results showed that tumors undergoing resection after waiting
only 4 h had no significant fluorescence, whereas, tumors that
underwent resection after 12 h showed a strong tumor-specific
red fluorescence (10). These results differed from Kennedy
et al. group who appreciated fluorescence of BCC tissue only
after 3 h from the application of topical 5ALA. The optimal
time required from the application of 5ALA to treatment was
still unclear and further clinical studies were needed. The
addition of solvents, such as Dimethyl sulfoxide (DMSO) and
Ethylenediaminetetraacetic acid (EDTA) to the topical ointment
was investigated by Peng et al. to determine if the use of these
solvents can enhance the absorbability and specificity of 5ALA
in tumor cells. They compared the topical application of 5ALA
containing 20% 5ALA alone to 20% 5ALA plus 20% DMSO and
4% EDTA in patients with BCC lesions. They found that 5ALA
alone was only located in the superficial layers in the lesion at 3 h
post-application and both the penetration into the deeper parts
of the lesion along with the degree of fluorescence was improved
in the patients who received 20% 5ALA plus 20% DMSO and
4% EDTA after similarly evaluating lesions 3 h post-application.
A 99% DMSO wash for 15min prior to the application of 20%
DMSO and 4% EDTA further enhanced the degree of penetration
and fluorescence.
Despite apparent accumulation in tumors and improvement
in surgical outcomes, 5ALA often showed poor delineation
of tumors from normal tissue (41). Poor correlation often
results from extension of the PpIX fluorescence beyond the
true margins of the tumor and non-specific accumulation in
benign lesions such as scars, sebaceous hyperplasia and others
(42, 43). A few studies have shown that the accumulation of
5ALA in tumors with an intact epidermis which is usually
seen in nodular BCC lesions is less compared to other types
of BCC lesions that typical have epidermal ulcerations. This
suggests that at the cellular level, the accumulation of 5ALA is
not tumor specific but may be related to increased epidermal
permeability and cellularity of tumors (44, 45). The use of esters
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of ALA, such as Methyl-ALA (MAL) improved delineation and
specificity of the BCC lesions most likely secondary to the
increased permeability of the molecule (43, 46, 47). Liposome
encapsulation of 5ALA further enhances the lipophilicity of
5ALA and requires less time for maximal fluorescence (∼2 h).
Although better demarcation of non-melanotic skin lesions
was found using liposome encapsulated 5ALA, the increased
lipophilicity increases false positives due to the accumulation
of Pp IX in sebaceous lesions, such as sebaceous hyperplasia
along with viral warts, lichenoid inflammation and melanocytic
nevi. Dense hairy areas also showed increased background
fluorescence suggesting that this method is not suitable in regions
with excess hair (42).
In addition to utility in BCC, topical 5ALA has also been
found useful for the demarcation of squamous cell carcinomas
(SCC) (48, 49). Delineation and complete excision of SCC lesions
can be more challenging compared to BCC lesions due to its
frequent irregular margins. Jeon et al. evaluated the use of 5ALA
in delineating tumor margins in 64 patients undergoing MMS.
Before the application of 5ALA, excessive crusts or scales were
scraped off the lesion without causing bleeding and then the
lesion cleaned with saline gauze. Nineteen patients received 20%
5ALA, 19 patients received 16% MAL and the remaining control
patients did not receive a photosensitizer. The incubation period
for the patients that received topical 5ALA was 6 h compared to
3 h for the patients received topical MAL. After the incubation
period, a Wood lamp (ultraviolet examination light, model
31602, 356 nm; Burton Medical Products Corp., Chatsworth,
CA) was used to determine the margins of the SCC lesion for
MMS. The results showed that after MMS, the number of stages
required for complete tumor removal was lower in the patients
that received either 5ALA or MAL. There was no significant
difference between 5ALA and MAL in terms of surgical benefits.
A surgical benefit was not seen in all patients that had high-
risk histologically SCC features, which may be due to irregular
infiltrative patterns for these, PpIX may not penetrate the deeper
layers and/or these cells do not produce as much PpIX compared
to the cells with histologically low-risk SCC features (48).
Appropriate 5ALA Dose and Route of
Administration in Dermatology
As discussed above, topical use is the most common application
of 5ALA in dermatology. Prior studies have used 5ALA ormethyl
ALA, mixed with DMSO/EDTA and or liposomal ALA. Further
clinical studies, however, are warranted to determine the optimal
clinical dermatology agent that should be used.
Imaging 5ALA Fluorescence in
Dermatology
Future development of imaging hardware and techniques to
improve PpIX visualization and differentiation of abnormal
tissue from normal tissue would be useful. Studies suggest auto-
fluorescence is reduced within tumor cells with an excitation
wavelength ∼370 nm and an emission wavelength around
455 nm which is different compared to normal tissue (50–52).
A few studies have shown improved 5ALA demarcation of BCC
lesions when measured in concert with reduced background
auto-fluorescence (50–52).
Conclusions and Future Applications of
5ALA Fluorescence in Dermatology
Studies have shown improved surgical outcomes with the use
of 5ALA in both photodynamic therapy and delineating tumor
margins in MMS, especially in BCC lesions. Fewer studies to date
have evaluated the use of 5ALA for SCC, though these studies
have shown that 5ALA has potential for improve visualization
of SCC. With a better understanding of the kinetics of 5ALA,
along with advancements in imaging techniques, 5ALA-mediated
visualization has potential for becoming standard practice in the
treatment of BCC and SCC lesions, along with expanding use to
other skin lesions such as melanoma (Figure 3).
OBSTETRICS AND GYNECOLOGY
First Application of 5ALA Imaging in
OB/GYN
Use of 5ALA in gynecologic cases now covers a broad spectrum
of procedures (54–56) since PpIX was shown to accumulate in
endometrial cancer cells by Wyss-Desserich and colleagues at
non-toxic doses in 1996 (57). In this study, fluorescence was
observed in vitro with best results found at 1 mg/ml incubated
for 24 h and excited at 488 nm.
There is variation with the amount of 5ALA induced PpIX
fluorescence in endometrium throughout the menstrual cycle.
Highest fluorescence values are seen in secretory endometrium,
followed by hyperplastic endometrium. In atrophic and
proliferative phase endometrium fluorescence intensity and rate
are the lowest (58).
Landmark Studies and Appropriate 5ALA
Dose/Route of Administration
Topical absorption of 5ALA is effective in patients with
cervical neoplasia (CIN) II and III, as well as with lichen
planus (55, 56). A cervical cap with 2–4mL of 200 mg/ml
5ALA placed for 1.5 h demonstrates that dysplastic cervical
tissue consistently has greater fluorescence than normal tissue.
This persists at 1.5, 3, and 6 h after exposure (55). In
Women with verified genital erosive lichen planus, 2ml vaginal
suppository of 6.25 mg/ml Hexyl 5-aminolevulinate applied
for 3 h shows successful conversion and accumulation PpIX.
Superficial fluorescence increases significantly in affected areas,
and while this is not statistically significant at 30min, it becomes
so at 3 h. Onmicroscopy, affectedmucosa has strong fluorescence
originating in submucosal inflammatory cells below the basal
membrane (56).
Ovarian carcinoma is a good candidate for early detection
with PpIX fluoroscopy as it commonly presents late in course and
metastasizes. After initial tumor removal, second look operations
can prevent recurrence. Intraperitoneal 5ALA solution given at
a concentration of 30 mg/kg 5 h before laparoscopy has been
evaluated as a route for administration and has shown systemic
distribution comparable to oral/topical preparations. In a third
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FIGURE 3 | Fluorescence imaging in dermatology. (A) Clearstone UV-DA, DigiMed Systems-Medical digital imaging system with ability to take ultraviolet photos.
Courtesy of DigiMed Systems. (B) Brightfield illumination vs. (C) fluorescence-overlay imaging of a facial basal cell carcinoma. [Intraoperative images courtesy of
Wan et al. (53)].
of patients with metastases seen at second look operations, PpIX
fluorescence was able to detect tumor in a majority of cases that
would otherwise have been missed with brightfield illumination
alone (59).
5ALA has also been used to delineate peritoneal
endometriosis, occasionally as an incidental finding. At doses as
low as 10 mg/kg administered orally 4–5 h before laparoscopy
there is increased concentration of PpIX fluorescence in
peritoneal lesions. These lesions are typically difficult to
visualize. 5ALA utility in OB/GYN is limited by increased PpIX
concentration in fimbriae and tubal tissue with unknown effects
on fertility (54).
Conclusion and Future Applications of
5ALA Fluorescence in OB/GYN
Overall these early studies have shown 5ALA-mediated
fluorescence in abnormal ovarian, endometrial, peritoneum
and vulva tissue (Figure 4). There is potential for widespread
and standardized use of 5ALA in OB/GYN especially as it
pertains to second look operations in ovarian carcinoma.
Further clinical studies are warranted to determine the
safety and efficacy of 5ALA-mediated tumor visualization
in OB/GYN.
HEAD AND NECK SURGERY
First Application of 5ALA in Head and Neck
Surgery
Identifying innovative approaches to labeling and visualizing
the borders of oropharynx and laryngeal neoplasms is a
significant area of interest in head and neck surgery. The
incidence of these neoplasms has increased during the last 2–
3 decades secondary to alcohol and tobacco abuse (61). Studies
show that survival rates increase with early stage carcinomas;
however, the diagnosis of a tumor at the primary stage can be
challenging. Earlier researchers used toluidine blue staining and
auto-fluorescence imaging to visualize these lesions. However,
Sabes et al. found a high false positive and false negative
rate with the use of toluidine blue for detecting oral lesions
FIGURE 4 | Fluorescence imaging in obstetrics and gynecology. (A) Karl Storz
D-Light fluorescence endoscopy system. (B) Laparoscopic image of
peritoneum with ovarian cancer metastases with fluorescence-overlay
imaging, Sote small fluorescent metastases (arrows) were histologically
consistent with tumor. [Intraoperative images courtesy of Yonemura et al. (60)].
which limited its widespread use. Similarly, Leunig et al.
found that autofluorescence between normal and malignant
tissue varied significantly between patients. Therefore, toluidine
blue staining and autofluorescence never became popular in
clinical use. Leunig et al. investigated the local use of 5ALA
in patients with head and neck tumors. In this study, 16
patients with histologically confirmed oral SCC were given an
oral rinse of 200mg 5ALA dissolved in 50ml of mineral oil.
A zero- degree endoscope (Art, Nr. 7200A; Storz, Tuttlingen,
Germany) with ultraviolet light filtered xenon-arc lamp system
along with an optimal multichannel analyzer (O-SMA 3; SI
Instruments, Gilching, Germany) was used to measure the
fluorescence contrast between tumor and normal tissue. In
all patients, protoporphyin IX fluorescence was detected and
significantly higher in the tumor compared to the surrounding
healthy tissue. Therefore, the use of oral 5ALA potentially
represented a new method for the early detection of oral
dysplastic and malignant lesions (61). This study’s promising
results initiated further research in the use of 5ALA in head and
neck surgery.
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Landmark 5ALA Studies in Head and Neck
Surgery
Since the first paper evaluating the use of 5ALA in head and
neck surgery in 1996, Leunig and other groups have continued
to investigate the use of 5ALA in head and neck surgery. In 2000,
Leunig et al. assessed the use of 5ALA for the detection of oral
SCC in 58 patients. These patients rinsed with a 0.4% solution
of 5ALA dissolved in mineral oil for 15min while closely being
supervised. After waiting for a 1 to 2.5 h period for incubation,
biopsies were taken from red fluorescence areas presumed to
represent tumor tissue along with tumor boundaries and normal
tissue using a modified 0◦degree endoscope equipped with a
filter (OG515, Schott, Mainz, Germany). In this study, the topical
use of 5 ALA had a sensitivity of 99% and a specificity of 60%
in detecting oral squamous cell cancer and dysplasia with no
direct side effects of 5 ALA. This study suggests 5ALA can be a
useful tool in the early detection of oral malignancy, but further
clinical studies were warranted (62). Zheng et al. later further
evaluated the use of 5ALA in detecting oral cancer lesions. Their
study included 49 patients with either clinically suspicious lesions
or pathologically proven malignancies of the oral cavity. The
patients rinsed with a 0.4% rinsing solution of 5 ALA dissolved in
mineral oil for 15min. After waiting for an incubation period of
1.5 to 2 h, all patients underwent fluorescence endoscopic-guided
biopsies. The malignant and dysplastic histological findings
closely correlated with PpIX fluorescence The sensitivity and
specificity with the use of 5ALA for separating benign tissue from
dysplasia was 92 and 96%, respectively. A sensitivity of 98% and
a specificity of 96% was achieved in distinguishing carcinoma
in situ from SCC with the use of 5ALA, and a sensitivity of 98%
and specificity of 92% for distinguishing carcinoma in situ and
squamous cell carcinoma from dysplasia was achieved with the
use of 5ALA (63).
The use of 5ALA for distinguishing laryngeal CA from benign
tissue has also been closely evaluated.Mehlmann et al. used a 5ml
0.9% NaCl solution of 5ALA topically applied in 16 patients with
suspected or histologically proven malignancies of the larynx
via a nebulized inhaler 1–2 h prior to a microlarnyngoscopy.
Microlaryngoscopy was performed through an optimized
endoscope (Hopkins 0, Art. No. KSTEXB001-3 or 27005AI,
Storz, Tuttlingen German) equipped with a special filter
system (D-light, Art No. 20133201, Storz) that was attached
to a footswitch that allowed switching between brightfield
illumination and fluorescence imaging. Forty-five biopsies were
taken. Areas of normal tissue appeared green in color whereas
malignant sites showed a strong red fluorescence. The sensitivity
and specificity of 5- ALA in separating normal tissue for
malignant tissue was 95 and 80%, respectively (64). This was the
first clinical study that showed 5ALA utility for the detection of
laryngeal cancer. Csanady et al. later further investigated the use
of 5ALA in detecting pharyngeal cancer. This study included 31
patients with either precancerous, malignant or benign lesions
of the laryngeal or hypopharyngeal cavities. Patients received
topical application of 1% 5ALA solution diluted with 0.9%
saline solution via nebulizer. After a 1.5–2 h incubation period,
fluorescence-guided endoscopic biopsies were performed. With
the use of 5ALA, the sensitivity and specificity of detecting
laryngeal and pharyngeal cancer from normal tissue was 96
and 76%, respectively. Hence, the laryngeal and hypopharyngeal
tumors and their margins were found to be accurately outlined
under fluorescence imaging showing the usefulness of 5ALA for
intraoperative visualization of neoplastic tissue (65).
Visualizing the parathyroid gland while operating in a
small space can be challenging, even for the most experienced
surgeons (66). Methylene blue was initially used for identifying
the parathyroid gland intraoperatively. However, its clinical
use is limited as it is associated with serious side effects
including: vascular pain, staining of the skin and urine,
and neurological toxicity (66). This intrigued Prosst et al.
to investigate the use of 5ALA in a 52 y.o female with
refractory secondary hyperparathyroidism for identifying the
parathyroid glands. The patient received 30 mg/kg of body
weight of 5ALA dissolved in water given orally 4 h prior
to surgery. After anterior cervical neck surgical exposure by
an otolaryngologists, a 4mm scope (30; Hopkins II; Karl
Stortz CO) connected to D-light fluorescence system was
brought into the operative field. Though the parathyroid
glands were unable to be identified under white-light mode,
they became clearly visible by their typical red fluorescence
under 635 nm illumination. The patient did not experience any
side effects from 5ALA (67). Suzuki et al. also investigated
5ALA’s fluorescence in normal parathyroid glands in 13 patients
with thyroid disease undergoing hemithyroidectomy. Patients
were orally administered 20 mg/kg body weight of 5ALA
dissolved in 10% glucose 5 h prior to surgery. After anterior
neck exposure, the room was darkened and the incision was
illuminated with a violet-blue light of 405 nm. In all 13
patients, parathyroid glands were easily identified by their red
fluorescence, even when they could not be detected under normal
light conditions (66). Takeuchi et al. further evaluated the use
of 5ALA for identifying parathyroid gland tissue in 20 patients
with primary hyperparathyroidism, 6 patients with secondary
hyperparathyroidism, and 3 patients with thyroid tumors and
normal parathyroid glands. All patients were administered oral
20 mg/kg 45min to 5 h prior to surgery. In the majority of the
cases, 5ALA accurately identified both normal and abnormal
parathyroid glands (68).
Appropriate 5ALA Dose and Route of
Administration
The preferred application of 5ALA fluorescence during head
and neck surgeries depends on the area of surgical interest.
For oral lesions, a 0.4% oral solution of 5ALA dissolved in
mineral oil rinsed for 15min followed by 1 to 2.5 h incubation
prior to illumination is the most common regime used (61–63).
A 0.4–1.0% 5ALA solution diluted with 0.9% saline topically
applied via a nebulized inhaler with an incubation period of 1–
2 h prior to a microlarnyngoscopy has been reported for oral
and pharyngeal lesions (64, 65). Whereas, for parathyroid and
thyroid surgery, 20–30 mg/kg of 5ALA given orally with an
incubation period between 45min to 5 h has been reported
(66–68). The safety of 5ALA, regardless of the administration
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route, has been questioned. Some studies suspected an increase
in serum creatinine levels after 5ALA administration; however,
this was refuted by Quon et al. when they concluded that the
increased creatinine levels represented a false elevation due to
substrate competition (69). Evidence in head and neck surgery
shows that 5ALA is safe with little to no side effects, with the
precaution to avoid sun exposure 24 to 48 h after ingesting 5ALA
to avoid the risk of skin bleaching and other phototoxic effects on
the skin and eyes (63, 70).
Imaging 5ALA Fluorescence in Head and
Neck Surgery
At the molecular level, 5ALA is metabolized by neoplastic or
highly metabolic tissues into protoporphyrin IX, a photosensitive
metabolite that is excited between wavelengths 375–440 nm and
subsequently emits fluorescence between 635 and 700n m (71).
The use of an endoscope equipped with a special filter system
attached to a footswitch that allows changing between brightfield
illumination and fluorescence excitation is the preferred method
for detecting the red fluorescence when 5ALA is applied in head
and neck surgery.
Conclusions and Future Applications of
5ALA in Head and Neck Surgery
The above studies suggest that 5ALA has potential for improving
the early detection of suspected oral and pharyngeal cancerous
lesions and may reduce operative time and rate of reoperation in
patients with parathyroid and thyroid disease. The disadvantage
of 5ALA is the need for patients to avoid sun exposure 24 to
48 h after exposure to 5ALA. More clinical studies are needed
to further validate the surgical benefits of 5ALA compared to
routine surgery before the use of 5ALA can become FDA-
approved for clinical practice in head and neck surgery.
GASTROINTESTINAL SURGERY
First Application of 5ALA in
Gastrointestinal (GI) Surgery
The use of 5ALA for photodiagnosis in gastroenterology
and gastrointestinal surgery, while broad and encompassing
esophageal, gastric, hepatic, and colorectal pathologies, has
not yet replaced established standard practice in this field.
Interestingly, its first use was aimed at a predominantly
preventive strategy during screening colonoscopies to identify
mucosal adenomas with malignant potential. Although
adenomas are benign, there is no method to distinguish between
benign and malignant lesions by conventional colonoscopy.
Therefore, Eker et al. (72) described the use of 5ALA to aid in
the differentiation of mucosal tissue, potentially as a means to
decrease cost and labor involved in removing benign lesions.
Of 57 selected patients undergoing laser-induced fluorescence
colonoscopy, 41 were ultimately included. Patients were given
oral ALA at 5 mg/kg and underwent the study after 2–3 h. A
nitrogen laser was tested at excitation wavelengths of 337, 504,
and 436 nm. The excitation of tissues at 337 nm was used, as
that wavelength yielded the maximum difference in emission
FIGURE 5 | Fluorescence imaging in Gastrointestinal Surgery. (A) Non-specific
peritoneal area under white light illumination. (B) Corresponding fluorescence
overlay image shows fluorescence foci histologically consistent with metastatic
gastric cancer (arrow). Images obtained with Karl Storz D-light endoscope
system. [Intraoperative images courtesy of Namikawa et al. (74)].
between normal and adenomatous tissue. All patient groups
were combined at the 337 nm wavelength, including patients
who were treated with 5ALA and those who were not. When
excited at 337 nm, the sensitivity for adenoma detection was
100% and the specificity was 96%. At the other wavelengths of
405 and 463 nm, the sensitivity and specificity were also higher
for 5ALA-treated patients than those without.
The application of 5ALA in predicting the malignant
potential of dysplastic epithelial cells associated with ulcerative
colitis also demonstrated an efficacious use of the fluorescent
molecule. One group evaluated the use of 5ALA to enhance
the detection of dysplastic tissue that may otherwise be missed
from the conventional standard of care, which is four-quadrant
random colon biopsies. In this study, 37 patients underwent
54 colonoscopies and received systemic oral ingestion, a local
enema, or a local catheter-directed spray form of 5ALA. The local
spray had the highest sensitivity of 100% for detecting malignant
tissue. Overall, this serves as a promising modality to increase
detection of dysplasia with a reduction of sampling error and
unnecessary random biopsies (73).
Landmark 5ALA Studies in GI Surgery
Similar to its use for colorectal cancer, endoscopic 5ALA
fluorescence has been explored as a surveillance method for
detecting dysplastic, pre-malignant tissue of the esophagus
(Barret’s), and more recently, assisting in laparoscopy-guided
resection of gastric and hepatic malignancies (Figure 5).
These studies have highlighted the growing number of 5ALA
applications in GI surgery while also demonstrating the mild,
transient adverse reaction profile with oral administration.
Much of the data pertaining to the use of 5ALA is for the
diagnosis and detection of dysplastic tissue in Barrett’s esophagus
during upper endoscopy. Barrett’s esophagus is the replacement
of normal esophageal epithelium (stratified squamous) to colonic
epithelium (simple columnar), typically due to chronic exposure
to acid reflux from the stomach. It is considered a premalignant
lesion and requires endoscopic surveillance with biopsy. The
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biopsy for Barrett’s esophagus is extensive: it involves obtaining
4 random quadrant biopsies for every 2 cm length of the
Barrett’s esophagus. The tissue within Barrett’s esophagus can
be classified as a range: nondysplastic, low grade dysplasia,
high grade dysplasia, to adenocarcinoma, but these cannot be
distinguished by gross examination with standard endoscopy.
Given the time and cost required to biopsy Barrett’s esophagus via
the conventional method, alternative methods are investigated to
better pinpoint dysplastic lesions, such as the use of ALA.
Brand et al. (75) evaluated the use of 5ALA to identify
dysplasia within Barrett’s esophagus, high grade dysplasia in
particular. Twenty patients with known Barrett’s esophagus were
given 5ALA at 10 mg/kg dissolved in orange juice 3 h prior to
endoscopy. A nitrogen laser at excitation of 400 nm was used at a
total of 97 mucosal sites. The use of 5ALA provided detection of
high grade dysplasia from normal tissue at 77% sensitivity and
71% specificity. In nodular high grade dysplasia the sensitivity
and specificity of 5ALA-mediated photodiagnosis approaches
100%. Although the use of fluorescence endoscopy may assist in
identification of these high grade lesions, there is no definitive
data that suggest its use is superior to random biopsies.
Stepinac et al. (76) performed a similar study investigating
the fluorescence detection of dysplasia and early cancer in
Barrett’s esophagus using 20 mg/kg of 5ALA vs. conventional
random four-quadrant biopsy. Twenty-eight patients with
known Barrett’s esophagus were selected for the study. All
patients first underwent conventional endoscopy with random
four quadrant biopsies at 1 cm intervals approximately 4–6 weeks
prior to fluorescence endoscopy. A total of 532 biopsies were
taken. During fluorescence endoscopy, a total of 178 biopsies
were taken, 81 in fluorescent regions and 97 in non-fluorescent
regions. The sensitivity and specificity of fluorescence-guided
biopsies were 100 and 63%, respectively. Fluorescence endoscopy
identified 5 low grade dysplasia lesions that were not identified
by conventional biopsy. Conventional biopsy identified 3 low
grade dysplasia lesions that were not detected during fluorescence
endoscopy. Both the conventional and 5ALA methods were able
to identify high grade dysplasia and adenocarcinoma, but neither
is ideal for identification of low grade dysplasia. However, the use
of ALA and fluorescence endoscopy may result in fewer biopsies
needed to achieve the same diagnosis (81 biopsies vs. 531).
Although the incidence of gastric cancer has decreased
overall, it remains one of the most common cancers worldwide.
It commonly spreads by peritoneal seeding. The presence of
peritoneal dissemination can alter the treatment decision-making
between surgery and chemotherapy. In patients with locally
advanced disease, performing a staging laparoscopy can help
guide treatment. Staging laparoscopy has a sensitivity of ∼30–
40% for peritoneal seeding. Kishi et al. (77) has evaluated the
use of 5ALA to enhance the tumor detection rate in advanced
gastric cancer. Thirteen patients with known gastric cancer were
selected to undergo staging laparoscopy. They are given 1 g
5ALA 4 h prior to laparoscopy. The detection rate for metastatic
lesions using 5ALA had a sensitivity of 93% and a specificity of
100%. However, there were inconsistencies in the detection of
the primary tumors. Although all primary tumors with serosal
invasion were detected, 5ALA failed to help identify two primary
tumors without serosal invasion and two primary tumors with
adjacent organ invasion. This emphasizes the limitation of the use
of visible wavelength fluorescence imaging, for while it is useful
in detecting surface tumors, it may not visualize tumors that are
deeply embedded in tissue.
In 2017, Ushimaru et al. (78) performed 5ALA-assisted
staging laparoscopy on 113 patients with advanced gastric
cancer and based their treatment strategies on the results of
the laparoscopy. They retrospectively evaluated the outcomes,
and identified predictive factors for peritoneal metastasis. All
patients were given 1 g 5ALA 3–5 h prior to laparoscopy.
Observation of abdominal cavity using white light and blue
light was done using the Storz D-light System laparoscope.
Patients noted to have peritoneal metastasis and/or positive
cytology, as diagnosed by 5ALA staging laparoscopy, underwent
chemotherapy and an interval gastrectomy if a later laparoscopy
revealed negative peritoneal disease. Those without metastasis
or cytology underwent definitive gastrectomy during the same
procedure. Patients with no peritoneal metastasis had a similar
estimated survival than patients with peritoneal metastasis only
seen with 5ALA. Factors that were predictive for metastasis were
advanced T stage, diffuse-type histology, ascites, and female sex.
This study suggests that the use of staging laparoscopy with 5ALA
may enhance the diagnostic accuracy for advanced gastric cancer
patients and thereby improve their overall treatment outcome.
5ALA-mediated photodiagnosis of hepatic tumors is currently
being explored. Kaibori et al. (79) evaluated a total of 134 patients
undergoing hepatic resections. They compared the utility of both
5ALA and Indocyanine Green for the intraoperative detection
of tumors. Although Indocyanine Green had higher sensitivity
of tumor detection (96% vs. 57%), the specificity of detection
by 5ALA was 100%. One limitation of photodiagnosis for solid
organ tumors is short distance of penetration. 5ALA mediated
fluorescence only penetrates 2–5mm of tissue, limiting its use
to superficial tumors. The adverse effects, while transient and
self-limited, may also deter patient participation.
A serious complication of hepatic resection is postoperative
bile leak. Inoue et al. (80) evaluated 737 patients who underwent
hepatic resections. Of these, 109 patients were given oral
1 g 5ALA dissolved in 20ml of 50% glucose approximately
3 h prior to hepatic resection, which is excreted in the bile.
Intraoperatively, patients were evaluated for leaks after resection,
first by gross evaluation then by blue light (405 nm) illumination.
Fluorescence imaging using 5ALA increased the intraoperative
detection rate of bile leaks from 8.3 to 13.7%. Given the mildly
increased detection rate, more studies will be needed to justify
routine use of 5ALA.
Appropriate Dose of 5ALA and Route of
Administration
The optimal dosing of 5ALA in the upper and lower GI tract
did not vary significantly from that which was historically used
in non-GI related malignancies. Since its earlier application
for the photodiagnosis of colorectal (72, 73) and esophageal
carcinoma (75, 76), oral administration of 5 and 10 mg/kg,
respectively, demonstrated superior sensitivity and specificity in
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identifying neoplastic tissue on par with that of tradition biopsy-
based surveillance methods. Oral administration of even greater
amounts of 5ALA up to 1 g for its more recent gastric and hepatic
applications (77–80), including the fluorescence of post-resection
bile leaks, has shown equal efficacy.
Conclusions and Future Applications of
5ALA in GI Surgery
Although there is promising data regarding the use of
photodiagnosis in gastroenterology and general surgery, there
lacks conclusive data to push its use into standard practice. More
randomized control trials with larger patient samples are still
needed at this time.
CARDIOTHORACIC SURGERY SECTION
First Application of 5ALA in Cardiothoracic
Surgery
The first study examining 5ALA’s ability to detect early stage
lung cancer was published in 1996 by Baumgartner et al. (81).
In this study, Baumgartner administered 5–10 wt% (250–500mg
5ALA in 0.5ml isotonic saline) through a medical nebulizer
to 7 patients with positive or suspicious sputum cytology,
but negative white light bronchoscopy, for inhalation for 30–
40min followed by fluorescence bronchoscopy after 3 h. An
ultraviolet light with 406.7–413.5 nm was used for excitation.
A target integrating color CCD video camera was adapted
to the bronchoscope and captured emission wavelength of
635 nm and 705 nm. Baumgartner calculated that the amount of
5ALA inhaled within lung tissue was independent of patients’
breathing patterns. Thus, patients can have a wide range of
pulmonary function without concern for variability in 5ALA
concentration. A peak plasma blood PpIX concentration was
found at 3.5 h after inhalation. No side-effects were observed in
the 7 patients. A total of 30 tissue samples were taken which
showed nine tumors, including seven carcinoma in situ, by PpIX
fluorescence. Sensitivity was 100% and specificity ranged from 30
to 50% due to five tissue samples exhibiting weak fluorescence
with indeterminate diagnoses. This study showed that 5ALA
inhalation was safe, could mediate detection of carcinoma in situ
within lung tissue, and may be used to assist diagnosing early
bronchial malignancies.
Follow-Up Study Using Inhaled 5ALA for
Bronchial Tumors
Following Baumgartner’s study of 7 patients, Piotrowski et al.
performed a perspective feasibility study on safety and efficacy
of 5ALA for diagnosing bronchial neoplasms (82). Forty-
nine patients, divided into four groups, inhaled either 5 or
10ml of 5ALA solution 3 h before bronchoscopy examination.
Xenon short arc lamp with a special filter system was used
for fluorescence excitation (λex = 375–440 nm) along with an
integrated filter that blocked remitted excitation (long pass =
440 nm). Groups consisted of laryngo-tracheo-bronchial tumors
that were previously diagnosed by conventional diagnostic
modes (n = 17); patients with prior surgery due to bronchial
tumors (n = 6), patients with prior surgery for laryngeal
cancer (n = 4); and present or ex-heavy smokers without signs
of tumor in conventional examinations (n = 22). There was
no significant difference between pre and post FEV1 values.
The overall sensitivity of 5ALA was 82% and specificity was
62% for all groups, PPV of 45% and NPV of 90%. When
brightfield illumination (WLB) plus 5ALA was compared with
brightfield alone, there was an increase in sensitivity by 2.1%
and NPV by 6%, but decreased specificity by 35.4% and
PPV by 53.1%. When the heavy smoker group was excluded
(due to increased number of false positives), the WLB+5ALA
sensitivity increased by 22% andNPV by 34%, whereas specificity
decreased by 26% and PPV by 35%. Due to its higher sensitivity,
5ALA was able to identify recurrent SCC in one patient
and a synchronous lesion in another patient that were WLB-
negative. Because of the high number of false positive samples,
authors concluded that 5ALA should not be used for screening.
Rather in combination with WLB, it could be used to guide
the physician in choosing proper sites for biopsy due to its
higher sensitivity and NPV. Additionally, in this study 5ALA
induced transient bronchial obstruction in 2 patients from
the heavy smokers group that was reversed with short acting
beta agonists.
5ALA Fluorescence for Staging Pleural
Malignancies in Patients With Inconclusive
Pleural Effusions
Thoracoscopy is often used in patients with negative pleural
fluid examinations for staging of malignancies. However, some
cases still remain undiagnosed or understaged (83). In 2006,
Baas et al. in a feasibility study, incorporated fluorescence
and white light inspection on 26 patients with non-diagnostic
pleural effusions to test 5ALA’s efficacy in diagnosing and
staging of pleural malignancies. Three patients were excluded
either due to multiple adhesions within thoracic cavity or
inability to perform endoscopic inspection. Patients ingested
a 2,000 to 2,500mg capsule of 5ALA depending on body
weight followed by thoracoscopy 3–4 h later. Fluorescence
images were recorded using the D-LIGHT System with <500 nm
for excitation and long-pass filter (470 nm long-pass). In 23
patients, a total of 111 biopsies were taken. Fifteen patients
were diagnosed with malignant mesothelioma, 5 with metastases.
Three patients had benign plaques and one with empyema.
One patient who did not receive initial diagnosis developed
mesothelioma 6 months later. A discrepancy between white light
and 5ALA occurred in 37 biopsies and further analysis showed
there was no improvement using 5ALA to obtain diagnosis.
However, with 5ALA, 4 patients upstaged their diagnosis
through detection of small lesions (<3mm) throughout the
parietal and visceral pleura as well as the collapsed lung.
Complications occurred in 3 patients from thoracoscopy. No
side-effects were reported using 5ALA besides grade 1 skin burn
in 3 patients 28 to 36 h after 5ALA intake. Authors showed
that 5ALA can help improve staging in patients with pleural
malignancy and could help guide in choosing proper biopsy sites
during thoracoscopy.
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In another study of undiagnosed pleural effusions by Pikin
et al. 23 patients with non-conclusive pleural effusions received
25 mg/kg of 5ALA 3 h before video-assisted bronchoscopy
(84). A total of 118 biopsies were taken. Both white light
and fluorescence thoracoscopy detected pleural deposits in
20 patients but fluorescence was able to detect additional
lesions in 12 of the 20 patients. In three other patients with
macroscopically normal pleura by white-light mode, 5ALA
detected micrometastases in one patient that was metastatic
lung adenocarcinoma by histological examination. Results from
combined conventional and florescence thoracoscopy showed
specificity of 88.4%, sensitivity of 89.1% and diagnostic accuracy
of 88.9%—results much higher than other studies. Authors
pointed out that detecting additional lesions in patients with
macroscopic pleural spread does not influence outcome in the
majority of cases. However, detection of pleural micometastases
in patients with peripheral lung cancer and visceral pleural
invasion could improve pre-operative approaches and
possible outcomes.
Pharmacokinetics of Inhaled 5ALA for
Optimum 5ALA-Induced Protoporphyrin IX
Fluorescence in Bronchial Tissue
In Baumgartner et al.’s 1996 study, he first showed that 5ALA
was safe for inhalation. In a follow-up study, Hautmann et al.
examined in vivo kinetics of inhaled 5ALA that generate the
greatest difference in fluorescence between tumor and adjacent
bronchial tissue. Nineteen patients with known or suspected
bronchial carcinoma are given 200mg of 5ALA dissolved in 5ml
of isotonic NaCl via inhalation. Patients are then randomized to
1,2,3,4, or 6 h before bronchoscopy under local anesthesia.
Excitation wavelength of 380–440 nm was used and emission
greater 630 nm, with a peak emission at 635, were measured
using Optical Multichannel Analyzer (OMA). Spectroscopy was
then analyzed on all macroscopically suspicious areas and areas
showing porphyrin fluorescence. A total of 38 biopsies were
taken that showed sensitivity that is almost twice that of
white light, but with a significant decrease in specificity. This
decrease in specificity was explained by the uptake of 5ALA by
inflammatory lesions. Spectroscopy showed that normal tissue
showed amaximum fluorescence 200min after 5ALA application
and lesions with moderate dysplasia at 160min after 5ALA
application. The spectral data showed significant difference
between lesions with moderate dysplasia and normal, as well as
lesions with moderate dysplasia and lesions with mild dysplasia
80 to 270min after 5ALA inhalation. During this time interval,
5ALA fluorescence in lesions with moderate dysplasia can exhibit
fluorescence values 5 times higher compared to the normal tissue.
No difference was seen in lesions with mild dysplasia and normal
tissue (85).
5ALA Facilitates Differentiation of Primary
Lung Cancer With Pleural Invasion
Kitada et al. recruited a total of 40 patients diagnosed pre-
operatively with lung cancer to undergo white light and
5ALA-mediated photodiagnosis. Patients consisted of 28 cases
with primary lung cancer, 8 with metastatic lung tumors, 2
with malignant pleural tumors, and 2 with benign tumors.
All lung metastases on the pleural surface, pleural malignant
mesotheliomas and benign tumors were visualized under red
fluorescence. For primary lung tumors, red fluorescence was
confirmed in 15 of 28 patients (53.5%). All P11–P13 (ranging
from tumor invading beyond elastic layer to tumors invading
parietal pleura) tumors were visualized (10/10). However,
visualization decreased to 5/18 (27.7%) for p10 cases (tumor
within subpleural parenchyma or superficial invasion of pleural
connective tissue). These 5 cases had been previously diagnosed
as p11. Authors showed that 5ALA enhances accurate diagnosis
of malignant lesions on the pleural surface as well as detection
and localization of small disseminated lesions and small
metastatic tumors to the lung (86).
Current Status and Future Directions of
5ALA in Cardiothoracic Surgery
Currently, 5ALA is still used as a research tool for photodynamic
diagnosis in cardiothoracic surgery. Future direction of 5ALA
includes a possible of direct comparison of brightfield vs.
5ALA-mediated fluorescence bronchoscopy in a randomized
control trial to determine which yields higher sensitivity
and/or specificity.
Conclusion
Clinical studies show 5ALA photodynamic diagnosis yields
higher sensitivity but lower specificity in identifying lung and
pleural malignancies. When added with conventional brightfield
illumination, 5ALA can help visualize small primary tumors
(<3mm), small lung metastases and primary lung cancer with
pleural invasions. 5ALA may prove useful for guiding surgeons
to specific biopsy sites and in the upstaging of tumors.
DISCUSSION
The clinical use of fluorescent molecules dates back to the start
of the twentieth century. Coined “Photodynamic Wirkung,”
or photodynamic phenomenon, European scientists first
described how to utilize these molecules to macroscopically
label abnormal tissue (87). While initially a conceptual
application, this methodology has driven numerous oncologic
investigations of naturally derived fluorescent molecules.
Hematoporphyrin derivatives were introduced in the mid-
twentieth century as potentially valuable diagnostic tools and
treatment modalities. Early studies conducted by Lipson and
colleagues (88) using rudimentary, yet novel, endoscopic devices
to differentiate neoplastic cells from normal tissue further
developed our understanding of hematoporphyrin derivatives
in the surgical setting. Currently FDA-approved for its use is
glioma surgery, 5ALA has undergone significant advances in its
applications to include neurosurgical, head and neck, urological,
cardiothoracic, gastrointestinal, and OB/GYN surgery. This
historical review of clinical studies highlights the rapidly
expanding role of 5ALA in the diagnosis and treatment of
neoplastic disease.
Frontiers in Surgery | www.frontiersin.org 12 September 2019 | Volume 6 | Article 45
Georges et al. Historical Review of 5ALA-Guided Surgery
Within each surgical field, studies have outlined the
advantages and disadvantages 5ALA-mediated photodiagnosis.
Due to its ubiquity in the heme synthesis pathway of all
cells, and preferential accumulation of PpIX within neoplastic
cells, the route and dosage of 5ALA has minimally varied.
Intra-venous, oral, intra-peritoneal, intra-vaginal, inhaled, and
topically administered 5ALA all demonstrate a similar optimal
dosing (5–30 mg/kg), and often, dose-dependent responses. For
many 5ALA applications, maximum dose are determined not by
increased adverse reactions, but rather plateauing of sensitivity
and specificity in neoplastic cell labeling. This phenomenon
seems intuitive given 5ALA’s role as a naturally occurring PpIX
precursor. Studies have noted relatively benign and avoidable
adverse reactions including bronchospasm with inhaled variants,
and photosensitivity most prevalent with topical and oral
administration of 5ALA. Regardless of route of administration,
the sensitivity of 5ALA photodiagnosis has varied from 83%
with low doses in urologic dysplasia to 100% for most other
applications. Albeit rare, a notable disadvantage of using
5ALA is represented in its poor specificity in differentiating
moderate dysplasia or cells exhibiting inflammatory changes
from normal tissue or higher-grade dysplastic lesions. This
limitation is most apparent in labeling urothelial carcinoma
and BCC/SCC, resulting in high false positive rates due
to epithelial hypercellularity or inadequate depth of topical
penetration, respectively. In order to ameliorate non-specific
labeling observed with these applications, the composition of
5ALA delivery systems (liposomal) and solvents (EDTA or
DMSO) are continuing to be evaluated.
Imaging devices used to visualize 5ALA uptake and
PpIX fluorescence are also advancing in their design
and implementation. In early clinical applications of
hematoporphyrin derivatives, such as PpIX, for malignancies of
the upper GI and cardiopulmonary systems, a 400-watt mercury
lamp transmitted white light via glass fiber cables through which
excitatory (∼400 nm) wavelengths were separated by a quartz rod
placed in a rigid bronchoscope (88). Using optical filters in the
form of glasses or eye-shields, the surgeon would then visualize
only red-fluorescence wavelengths corresponding to PpIX.
Current-day fluorescence-guided surgery using commercially
available wide-field microscopes is significantly less cumbersome
and utilizes more sensitive short pass and long pass filters
integrated within the system. Additional imaging hardware
designs have aimed to improve on the historical limitations
of using 5ALA in its various surgical contexts. While still
investigational, newer imaging hardware optimizes the resolution
of PpIX in either islands of neoplastic cells or areas of lower-grade
lesions where PpIX fluorescence may not be as robust as that of
higher-grade lesions. The largest obstacles toward this goal have
been to mitigate signal-to-noise ratio of autofluorescent tissue
and to achieve a greater sensitivity in localizing deep, labeled
tissue (89).
Administration of 5ALA has granted surgeons withinmultiple
subspecialties the ability to more accurately visualize malignant
tissue during surgery. The vast data from studies collected
during the past 6–7 decades is representative of 5ALA’s small
side effect profile and reliable efficacy. The growth of 5ALA’s
intraoperative applications during this timeframe has been
paralleled by advancements in imaging technology focused
on improving PpIX visualization. These clinical trials suggest
5ALA is a relatively safe molecule for generating intraoperative
photodiagnosis of malignant tissues across multiple surgical-
oncology subspecialties.
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